Physician profile
Barry M Arkin
NPI 1417904202
$2,946.61
in general payments reported to CMS, 2019-2025
24 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,714 · 2020: $313 · 2021: $27.68 · 2022: $561 · 2023: $206 · 2024: $23.14 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $817.60 | 2019-2023 | |
| Boston Scientific Corporation | $378.28 | 2019-2022 | |
| Pfizer INC. | $271.88 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $213.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $161.88 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $145.62 | 2019-2022 | |
| Novo Nordisk INC | $129.12 | 2022-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.78 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $115.24 | 2019 | |
| Amgen INC. | $95.56 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $87.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.78 | 2019-2022 | |
| Abbott Laboratories | $63.82 | 2019 | |
| Esperion Therapeutics, INC. | $42.94 | 2023 | Nexletol |
| Philips North America LLC | $42.02 | 2020-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $31.57 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $30.81 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.77 | 2023 | |
| Neural Analytics, INC. | $22.42 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Merck Sharp & Dohme LLC | $16.96 | 2023 | Verquvo |
| Amarin Pharma, INC. | $16.55 | 2019 | |
| Scpharmaceuticals INC. | $16.38 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $14.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Arkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.